We are live on ! Find out more
PVLA

Palvella Therapeutics
PVLA

27 hedge funds and large institutions have $50.4M invested in Palvella Therapeutics in 2017 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 3

78% more capital invested

Capital invested by funds: $28.3M → $50.4M (+$22.1M)

75% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 4

13% more funds holding

Funds holding: 24 → 27 (+3)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.02% less ownership

Funds ownership: 0.59% → 0.56% (-0.02%)

Holders
27
Holders Change
+3
Holders Change %
+12.5%
% of All Funds
0.67%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
9
Increased
7
Reduced
4
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Renaissance Technologies
Renaissance Technologies
New York
+$563K
2
SFM
Sphera Funds Management
Israel
+$420K
3
EI
EAM Investors
California
+$404K
4
BlackRock
BlackRock
New York
+$198K
5
LOAMU
Lombard Odier Asset Management (USA)
New York
+$170K

Top Sellers

1
SM
Sabby Management
Florida
-$1.81M
2
TCM
Tekla Capital Management
Massachusetts
-$455K
3
DCM
DAFNA Capital Management
California
-$376K
4
OC
Oppenheimer & Co
New York
-$23K
5
VKH
Virtu KCG Holdings
New York
-$20K
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$18.9M – – –
TCM
2
Tekla Capital Management
Massachusetts
$10.2M -$455K -2,573 -5%
LOAMU
3
Lombard Odier Asset Management (USA)
New York
$6.5M +$170K +963 +3%
BI
4
BVF Inc
California
$4.98M +$138K +778 +3%
OFM
5
Omega Fund Management
Massachusetts
$4.41M – – –
SFM
6
Sphera Funds Management
Israel
$2.6M +$420K +2,375 +23%
Renaissance Technologies
7
Renaissance Technologies
New York
$661K +$563K +3,180 New
Morgan Stanley
8
Morgan Stanley
New York
$499K +$21.6K +122 +5%
EI
9
EAM Investors
California
$475K +$404K +2,284 New
BlackRock
10
BlackRock
New York
$233K +$198K +1,120 New
Deutsche Bank
11
Deutsche Bank
Germany
$169K +$145K +817 New
Creative Planning
12
Creative Planning
Kansas
$156K +$30.3K +171 +30%
DCM
13
DAFNA Capital Management
California
$139K -$376K -2,123 -76%
TC
14
TFS Capital
Pennsylvania
$85K +$72.4K +409 New
Geode Capital Management
15
Geode Capital Management
Massachusetts
$68K +$29.6K +167 +104%
RC
16
RBF Capital
California
$65K – – –
JP Morgan Chase
17
JP Morgan Chase
New York
$61K +$52K +294 New
PAM
18
Panagora Asset Management
Massachusetts
$52K – – –
Bank of America
19
Bank of America
North Carolina
$46K – – –
RJA
20
Raymond James & Associates
Florida
$39K +$33.3K +188 New
FFEC
21
First Financial Equity Corporation
Arizona
$28K +$22.1K +125 New
LAM
22
Lebenthal Asset Management
New York
$26K – – –
AIM
23
Acrospire Investment Management
Illinois
$14K -$2.3K -13 -16%
Manulife (Manufacturers Life Insurance)
24
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$7K – – –
UBS Group
25
UBS Group
Switzerland
$4K -$16.3K -92 -82%
1
2

PVLA Hedge Fund Activity: Q1 2017 in Review

27 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q1 2017, worth a combined $50.4M — up 78% from $28.3M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new PVLA positions and 3 closed out — a net gain of 6 holders — while 7 added to existing stakes and 4 trimmed.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $563K. The largest seller was Sabby Management, exiting entirely with an estimated $1.81M sold.

  • 27 institutional investors held Palvella Therapeutics (PVLA) as of Q1 2017, up from 24 in Q4 2016.
  • Funds reported $50.4M of Palvella Therapeutics stock for Q1 2017, up 78% quarter-over-quarter.
  • 9 funds opened new Palvella Therapeutics positions in Q1 2017 and 3 closed out, a net change of +6 holders.
  • The largest Palvella Therapeutics buyer in Q1 2017 was Renaissance Technologies, an estimated $563K added.
  • The largest Palvella Therapeutics seller in Q1 2017 was Sabby Management, an estimated $1.81M sold.

Based on aggregated 13F filings for Q1 2017.